The first human trial of a novel class of anticoagulants shown to be as effective as blood thinners like Xarelto and Eliquis but with much fewer adverse bleeding effects is scheduled to begin soon in Australia. The new class has successfully completed regulatory toxicology studies and was well-tolerated after a 28-day repeat dosing.
VE-1902, developed by Verseon, is in a new class of drugs called PRecision Oral AntiCoagulants, or PROACs. If results of clinical trials are favorable, V-1902 could have a major impact on the treatment of cardiovascular diseases by becoming the first blood thinner suitable for long-term anticoagulation-antiplatelet combination therapy.
Candidates for these drugs include those with acute coronary syndrome or patients with non-valvular atrial fibrillation with coronary artery disease.
Finding an oral anticoagulation medication that can be safely co-administered with antiplatelet drugs has been difficult due to the high risk of bleeding that Xarelto and Eliquis carry. If the success of VE-1902 holds, “these new precision anticoagulants could improve the standard of care for the millions of patients who need prolonged anti-clotting therapy to reduce major adverse cardiac complications,” Keith Fox, Duke of Edinburgh Professor of Cardiology at the University of Edinburgh, told Cardiac Rhythm News.
Xarelto and Eliquis are in a class of blood thinners called Factor Xa inhibitors. They are used to prevent strokes in patients with atrial fibrillation, to treat and prevent deep vein thrombosis and pulmonary embolism, and to prevent blood clots in patients who have recently undergone hip or knee replacement therapy. The drugs can cause serious bleeding events including gastrointestinal bleeds and brain bleeds.
Source: Cardiac Rhythm News